Bert Spilker's Pharma Principles of The Week
Posted by: Bert Spilker
- Business decisions for advancing or terminating an investigational drug in development or a compound in discovery are best made using “minimally acceptable standards.” These are primarily established by marketing groups, with input from R&D.
- Do your best to eliminate fads and hype in management styles and be skeptical of all claims by vendors.
- Truly great scientists do not generally make great managers. Creative scientists must be encouraged, stimulated and rewarded so they are happy to remain creative scientists.
Bert Spilker , PhD, MD is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA. He is the founder of Bert Spilker & Associates (BS&A).